Tarsus Pharmaceuticals, Inc. (TARS)
Tarsus Pharmaceuticals, Inc. (TARS) from its SEC filings: 2025 revenue $451.4 million (+147% vs the year before), net margin -15%, free cash flow -$22.3 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Revenue (2025) | $451.4 million |
| Revenue growth | +147% |
| Net income | -$66.0 million |
| Net margin | -14.6% |
| Free cash flow | -$22.3 million |
| Diluted EPS | $-1.59 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +69% |
| Cash | $204.6 million |
| Long-term debt | $72.8 million |
| Share count, 1 year | +4% |
| Fundamentals check | Mixed fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-24. Education only, not financial advice.